Validation of a modified pre‐lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B‐non Hodgkin lymphoma-Reference-Cited by-同舟云学术

Validation of a modified pre‐lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B‐non Hodgkin lymphoma

Published:2020-06-12 Issue:5 Volume:98 Page:385-398
ISSN:1552-4949
Container-title:Cytometry Part B: Clinical Cytometry
language:en
Short-container-title:Cytometry

Author:

Bayly Emma¹²,Nguyen Vuong¹,Binek Adrian¹,Piggin Anna¹²,Baldwin Kylie¹,Westerman David¹²³,Came Neil¹³^ORCID

Affiliation:

1. Pathology Department Peter MacCallum Cancer Centre Melbourne Victoria Australia

2. Clinical Haematology Victorian Comprehensive Cancer Centre Melbourne Victoria Australia

3. Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre The University of Melbourne Parkville Victoria Australia

Publisher

Wiley

Subject

Cell Biology,Histology,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cyto.b.21893

Reference37 articles.

1. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting

2. Optimization and validation of an 8‐color single‐tube assay for the sensitive detection of minimal residual disease in B‐cell chronic lymphocytic leukemia detected via flow cytometry;Dowling A. K.;Laboratoriums Medizin,2016

3. EuroFlow. EuroFlow Standard Operating Procedure (SOP) for Bulk Lysis for MRD panels. Version 1.3 (June 25 2018);https://euroflow.org/usr/pub/protocols.php.

4. Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity

5. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future;Cancers;2023-07-20

2. Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma;Current Treatment Options in Oncology;2023-05-30

3. Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia;British Journal of Haematology;2023-04-13

4. Real‐world utility of early measurable residual disease assessments by multi‐parametric flow cytometry in adult patients with B‐lymphoblastic leukemia receiving Hyper‐CVAD induction chemotherapy;European Journal of Haematology;2022-11-11

5. Identification of candidate targets and mechanisms involved in miRNA regulation in multiple myeloma;World Journal of Surgical Oncology;2022-01-26